Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

CAR-T-cell therapies/Glofitamab/Obinutuzumab

Hepatic inflammatory pseudotumour

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Calixto Alvarez Z, et al. Hepatic inflammatory pseudotumour (HIP) as immune response adverse event (irAE) in a patient with large B Cell lymphoma treated with cancer immunotherapies (bispecific antibodies -Obinutuzumab and Glofitamab- and CAR-T). Virchows Archiv 483 (Suppl. 1): S220, Sep 2023. Available from: URL: https://dx.doi.org/10.1007/s00428-023-03602-w [abstract] Calixto Alvarez Z, et al. Hepatic inflammatory pseudotumour (HIP) as immune response adverse event (irAE) in a patient with large B Cell lymphoma treated with cancer immunotherapies (bispecific antibodies -Obinutuzumab and Glofitamab- and CAR-T). Virchows Archiv 483 (Suppl. 1): S220, Sep 2023. Available from: URL: https://dx.doi.org/10.1007/s00428-023-03602-w [abstract]
Metadaten
Titel
CAR-T-cell therapies/Glofitamab/Obinutuzumab
Hepatic inflammatory pseudotumour
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-50372-5

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Teprotumumab

Case report

Tislelizumab

Case report

Naloxone